title: Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation.
abstract: BACKGROUND
  Cytomegalovirus (CMV) has long been recognized as the most common opportunistic pathogen in transplant recipients. The use of post-detection antiviral treatment of CMV as a strategy to prevent disease in cardiac recipients is becoming the standard policy. Valganciclovir is an oral pro-drug of ganciclovir, with a 10-fold greater bioavailability than oral gancyclovir.
  
  
  METHODS
  We reported our first experience with 8 patients (3 female, 45.0 +/- 10.5 years old, non-CMV mismatched) who underwent cardiac transplantation and had positive results of CMV polymerase chain reaction (PCR) within first 6 weeks after transplantation without concomitant CMV disease. These patients received valganciclovir in dosage 450 to 900 mg daily depending on renal function for 3 weeks. Standard immunosuppressive regimen consisted of cyclosporin A, MMF and corticosteroids, and was not changed after detection of CMV infection. In one patient we used sirolimus with respectively reduced dosage of cyclosporin A. Weekly measurements of CMV-PCR were performed to observe results of therapy.
  
  
  RESULTS
  After 1 week of valganciclovir therapy CMV-PCR plasma concentration in all patients decreased significantly (2,105 copies/ml vs 400 copies/ml; p < 0.0001). No relapse of CMV infection has been detected after completing of valganciclovir therapy with follow up duration of 9.0 +/- 0.92 months. The drug was generally well tolerated, and we did not observe any severe drug related adverse events.
  
  
  CONCLUSIONS
  Oral valganciclovir as pre-emptive antiviral therapy administrated after detection of CMV infection seems to be an effective and safe treatment in cardiac transplant recipients.
authors.affiliation: Department of Cardiothoracic Surgery, University Clinic of Surgery, University of Vienna, Vienna, Austria. elena.deviatko@akh-wien.ac.at
authors.forename: Elena
authors.initials: E
authors.lastname: Devyatko
authors.forename: Andreas
authors.initials: A
authors.lastname: Zuckermann
authors.forename: Margot
authors.initials: M
authors.lastname: Ruzicka
authors.forename: Arthur
authors.initials: A
authors.lastname: Bohdjalian
authors.forename: Georg
authors.initials: G
authors.lastname: Wieselthaler
authors.forename: Susanne
authors.initials: S
authors.lastname: Rödler
authors.forename: Ernst
authors.initials: E
authors.lastname: Wolner
authors.forename: Michael
authors.initials: M
authors.lastname: Grimm
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir